Introduction {#S0001}
============

More than 70% of the new cases of nasopharyngeal carcinoma (NPC) are found in East Asia and Southeast Asia.[@CIT0001] The non-keratinized subtypes constitute the majority of cases in the epidemic area (\>95%), which is mainly related to EBV infection. Due to the particular anatomical position of NPC, the main treatment is radiotherapy.[@CIT0002] Over the last several years, intensity-modulated radiation therapy (IMRT) has been broadly utilized for NPC treatment. The 5-year overall survival (OS) rate is 74.6--86.3%, but there still remain 10% local residual or recurrence rates.[@CIT0001]

There are many changes in nasopharynx tissue after radiotherapy, such as edema, inflammation and fibrosis. The residual lesions detected by biopsy or imaging can be composed of either tumor stem cells, tumor cells with lost proliferative ability, and other cell types.[@CIT0003] For patients with residual at the end of radiotherapy, the prognosis is significantly worse.[@CIT0004],[@CIT0005] For these patients, 3 months after treatment is considered as the time point at which to evaluate the curative effect. However, according to our clinical observation, the time of tumor regression varies among patients who chose to wait, and even some patients have a time of tumor regression greater than 6 months. The biological effect of IMRT is different from that of two-dimensional radiotherapy.[@CIT0006]--[@CIT0008] Also, after 3 months of observation, salvage treatment may not be effective because of the interruption of overall anti-tumor treatment. Patients with poor prognosis should be treated as early as possible to avoid treatment interruption. Therefore, we believe that there needs to be a new evaluation method to carry out risk stratification again at the end of radiotherapy in order to start the treatment of patients with poor prognosis as early as possible.

Most of the residual tumor is known to be located outside the nasopharynx. He et al[@CIT0009] studied 142 patients that had residual tumors after radiotherapy ended. Only 11.44% of the residual tumors were found in the nasopharynx cavity, while 30.93% were in the skull base, and 30.15% were in the parapharyngeal space and additional soft tissues. Additionally, 45.07% of patients had more than one residual tumor. In most cases, it is difficult to get a second biopsy of the tumor. Hence, clinicians have to depend on imaging to assess the effectiveness of treatment. Magnetic resonance imaging (MRI) has been considered as the recommended examination method for the diagnosis of NPC and delineation of the target area, which cannot be replaced by PET/CT scanning.[@CIT0010],[@CIT0011] It is suggested that the general accuracy of PET/CT and MRI in the diagnosis of local recurrence and residual NPC is higher, while MRI is more largely utilized in clinical practice.

To sum up, this study analyzed NPC patients with MRI-detected residual tumor at the end of IMRT and constructed an effective prognostic model to evaluate the prognosis of these patients.

Materials and Methods {#S0002}
=====================

Patient Selection and Staging {#S0002-S2001}
-----------------------------

In this study, 162 cases of NPC from the First Affiliated Hospital of Guangxi Medical University from January 2010 to December 2012 that were initially treated with IMRT and had residual tumor were included. All patients were diagnosed using biopsy and MRI and had a complete history, physical examination, chest CT, abdominal B-ultrasound, bone scan and routine laboratory examination. The results showed no distant metastasis. At the end of radiotherapy, MRI of the nasopharynx and neck indicated local or regional residual tumor. After radiotherapy, MRI of nasopharynx and neck was followed-up. Based on AJCC/UICC 8th Edition, combined with MRI and other examinations before treatment, the location of lymph nodes was determined by RTOG (2013 Edition) neck lymph node division method. Prior to treatment, two senior radiologists evaluated the films and identified clinical manifestations of the patients, such as whether there was cranial nerve invasion or cervical lymph node palpation. This study was carried out according to the ethical standards of Helsinki Declaration and approved by the ethics committee of the First Affiliated Hospital of Guangxi Medical University. This study is a retrospective study and does not have adverse effects on the rights and health of the participants, so the requirement of informed consent is waived. At the same time, patients' privacy and personal identity information are protected.

Treatment Strategy {#S0002-S2002}
------------------

All 162 patients received IMRT. First, CT localization was performed, ranging from top of the skull to the lower part of the clavicular head, which had a width of 3 mm. According to MRI, endoscopy and special conditions, the gross tumor volume of the nasopharynx (GTVnx) and gross tumor volume of the positive cervical lymph node (GTVnd) were determined. Clinical target volume-1 (CTV1) contains the whole nasopharynx mucosa and submucosa 5mm. The clinical target volume-2 (CTV2) contained high-risk structure on the basis of CTV1. Planning target volume (PTV) was expanded by 3--5mm on the basis of each tumor target. Spinal cord, brain stem, temporal lobe, pituitary gland, optic nerve, optic chiasmata, lens, eyeball, parotid gland were protected as endangered organs. The prescription dosage was pGTVnx 68--74Gy, pGTVnd 66--70Gy, pCTV1 60--66Gy, pCTV2 50--56Gy, 5 times/week, 30--33 times in total. As per the target area and dose design guidelines of IMRT for nasopharyngeal carcinoma (RTOG 0225), experts agreed to set the limited dose of crisis organ: crystal ≤8Gy, parotid d33 ≤35Gy, middle ear ≤50Gy, brain stem ≤54Gy, optic nerve ≤54Gy, optic chiasmata ≤54Gy, pituitary ≤54Gy, spinal cord ≤45Gy, temporal lobe ≤60Gy, mandible and temporomandibular joint ≤60Gy, and oral radiation should be as low as possible. Eclipse radiotherapy planning system determines the planning scheme. Varian 6-MV X-ray treatment. Chemotherapy drugs were mainly platinum, and induction chemotherapy, synchronous chemotherapy or adjuvant chemotherapy were conducted according to the condition of NPC patients.

Diagnostic Criteria of Local and Cervical Lymph Node Residual {#S0002-S2003}
-------------------------------------------------------------

MRI diagnostic criteria of residual tumors include residual tumors within the nasopharynx or additional soft tissues after radiotherapy that acts as low signal in T1 weighted imaging, and high signal and enhancement in T2 weighted imaging. If the diameter of the short axis of the neck lymph node is greater than 10 mm, the diameter of the retropharyngeal lymph node is greater than 5 mm, and it still exists at the end of radiotherapy, then the local lymph node is considered residual. If the skull bone is damaged and the degree and range of bone enhancement was not decreased compared with that before radiotherapy and chemotherapy, it is considered as a residual tumor.[@CIT0004] The residual tumor was determined by two head and neck radiologists and two radiotherapy doctors.

Follow-Up {#S0002-S2004}
---------

Follow-up methods include contacting patients or their families by telephone or according to medical records and various examinations. We checked on patients every 3 months within the first 2 years post-treatment, then every 6 months after 2--5 years, and finally, every year thereafter. The follow-up time was from treatment completion to either time of death or final follow-up. The overall survival (OS) was measured from the day radiotherapy was completed to the day of death or final follow-up. Physical examination, microscopic examination and MRI scanning were carried out. Any clinical manifestations, CT scan or bone scan of chest and liver were recorded. Tumor response rate was determined as per the response evaluation standard of solid tumor (RECIST) version 1.0.

Statistics {#S0002-S2005}
----------

Single-factor Cox regression model was used to identify the predictors, and multivariate Cox survival analysis using the backward stepwise method was carried out to identify the independent risk factors related to prognosis in the remaining patients. Additionally, the risk ratio and 95% confidence interval (CI) correlation were calculated. The prediction model was virtualized by using a nomogram, which, in turn, was predicted by C-index and time-dependent ROC.[@CIT0012] The C-index was corrected by bootstrap verification (1000 bootstrap resampling). According to the optimal cut-off value of the total score that produced the largest χ2 value in the Mantel--Cox test assessed by X-tile software (version 3.6.1; Yale University, New Haven, CT, USA),[@CIT0013],[@CIT0014] the patients were divided into high-risk and low-risk subgroups. Kaplan--Meier survival curve was used to compare the two groups. Hazard ratio (HR), 95% CI and log-rank p-value were recorded. SPSS 22.0 (IBM, New York, USA) and R software (version 3.5.2) with the "rms" package were used for statistics. P\<0.05 represented statistical significance.

Results {#S0003}
=======

Patient Characteristics and Single Factor Analysis {#S0003-S2001}
--------------------------------------------------

Among the 162 patients in this group, 62 (38.2%) patients achieved total remission 3 months post-treatment, and 51 (31.5%) patients achieved total remission 3--6 months post-treatment. The 3-year and 5-year survival rates (OS) were 78.3% and 66.9%, the recurrence-free survival rates(LRFS) were 91.5% and 87.3%, and the distance metastasis-free survival (DMFS) were 80.0% and 73.8%, respectively. Detailed baseline data are shown in [Table 1](#T0001){ref-type="table"}. Sex, age, WHO classification, chemotherapy, treatment, dose to GTVnx, dose to GTVnd, T stage, N stage, lymph node with fusion, lymph nodes with enhancing rim, lymph nodes necrosis and residual site were analyzed by single-factor analysis, and the results are depicted in [Table 1](#T0001){ref-type="table"}.Table 1Characteristics of 162 Patients and Univariate Regression AnalysisCharacteristicsCase Numbers (%)OSP valueHazard Ratio95% CISex Male132(81.5%)Reference---- Female30(18.5%)0.3450.6960.328--1.477Age ≥5057(35.2%)Reference---- \<50105(64.8%)0.0060.4710.275--0.808WHO classification I12(7.4%)Reference---- II48(29.6%)0.2922.2060.507--9.595 III102(63.0%)0.2342.3760.571--9.882Chemotherapy Yes145(89.5%)Reference---- No17(10.5%)0.0102.6271.259--5.481Treatment RT alone17(10.5%)Reference---- IC3(1.9%)0.5850.5630.071--4.444 CCRT76(46.8%)0.040.4450.206--0.963 IC+CCRT44(27.2%)0.0260.3660.151--0.884 CCRT+AC16(9.9%)0.770.8670.334--2.250 IC+CCRT+AC6(3.7%)0.1690.2350.030--1.853Dose to GTVnx \<71.2Gy76(46.9%)Reference---- ≥71.2 Gy86(53.1%)0.4341.2420.722--2.139Dose to GTVnd \<68.1 Gy71(43.8%)Reference---- ≥68.1Gy91(56.2%)0.381.280.738--2.219T stage T15(3.1%)Reference---- T222(13.6%)0.4280.4380.057--3.369 T3106(65.4%)0.6680.8220.336--2.011 T429(17.9%)0.2740.690.356--1.340N stage N013(8.0%)Reference---- N153(32.7%)0.2013.770.493--28.819 N277(47.6%)0.076.30.859--46.214 N319(11.7%)0.0379.011.140--71.207Lymph nodes with fusion No89(54.9%)Reference---- Yes73(45.1%)0.0811.620.943--2.784Lymph nodes with enhancing rim No134(82.7%)Reference---- Yes28(17.3%)0.0771.760.941--3.292Lymph nodes necrosis No110(67.9%)Reference---- Yes52(32.1%)0.0022.3231.353--3.986Residual site Nasopharynx residual83 (51.2%)Reference---- Cervical residual50 (30.9%)0.5671.2160.622--2.370 2 sites residual29 (17.9%)0.4211.3940.620--3.132[^1]

Multivariate Analysis and Construction of Nomogram {#S0003-S2002}
--------------------------------------------------

In Cox multivariate regression analysis, age, chemotherapy, N stage and lymph node necrosis were independent prognostic markers that affect NPC patients with residual tumor. The results are summarized in [Table 2](#T0002){ref-type="table"}. All these independent predictors were then incorporated into the nomogram. The nomogram integrated all these independent predictors, as shown in [Figure 1](#F0001){ref-type="fig"}. In the nomogram, each value of the model covariate is assigned a score of 0--100. Through the addition of the total scores of all these predicted factors in the total subscale, we can evaluate the prognosis of NPC patients with MRI-detected residue. Scores in detail for the nomogram are shown in [Table 3](#T0003){ref-type="table"}.Table 2Multivariate Regression Analysis of 162 PatientsCharacteristicsP-valueHazard Ratio95% CIAge ≥50Reference---- \<500.0030.4350.25--0.757Chemotherapy YesReference---- No0.0033.3191.492--7.381N stage N0Reference---- N10.1384.7660.604--37.583 N20.0517.4740.992--56.3 N30.02511.4861.358--97.123Lymph nodes necrosis NoReference---- Yes0.0082.2651.243--4.124[^2] Table 3Scores in Detail for the NomogramCharacteristicsAssignmentScoreAge ≥50149 \<5020Chemotherapy Yes10 No266N stage N000 N1133 N2267 N33100Lymph nodes necrosis No10 Yes249[^3] Figure 1Nomogram for predicting the prognosis of nasopharyngeal carcinoma with MRI-detected tumor residue at the end of IMRT.

Verification of Prediction Nomogram {#S0003-S2003}
-----------------------------------

Each variable has a score. Through evaluating the total score of all factors on the complete subscale, the probability of certain results can be determined by making a vertical line from the complete score. The C-index of the transfer nomogram is 0.724 (95% CI is 0.659--0.788). Through 1000 repeated bootstrapping test, the consistency index, corrected slope was 0.723, 0.861, respectively. Time-dependent ROC curve was utilized to verify the predictive nomogram, as shown in [Figure 3](#F0003){ref-type="fig"}. The AUC was 0.754, which indicates that the nomogram represents a feasible model for predicting NPC patient prognosis using an MRI-detected residual tumor. The standard curve for prognosticating patients with MRI-detected residual NPC also demonstrated suitable agreement among nomogram prediction and real-life observation, as shown in [Figure 2](#F0002){ref-type="fig"}. The calibration slope of predicting 3-year and 5-year overall survival was 1.006, 1.071, respectively.Figure 2Calibration curves used to compare the nomogram-predicted and actual survival probabilities at 3 (**A**) and 5 years (**B**). The actual overall survival (OS) is plotted on the y axis, while the nomogram-predicted probability is plotted on the x axis. The dotted line indicates the reference (i.e., ideal prediction). The calibration slope of A and B was 1.006, 1.071, respectively.Figure 3Operating characteristic curves (ROC) of the prediction nomogram.

Recognition of High- and Low-Risk Population in Patients with Residual NPC {#S0003-S2004}
--------------------------------------------------------------------------

All patients were separated to either low-risk (score \<149.1) and high-risk group (score ≥149.1). There were 141 cases in the low-risk group and 21 cases in the high-risk group. It is noted that the Kaplan--Meier survival curve showed that OS and DMFS in the high-risk group were substantially reduced compared to those in the low-risk group (P\<0.000), as shown in [Figure 4](#F0004){ref-type="fig"}.Figure 4Overall survival curves (**A**) and distant metastasis-free survival curves (**B**) for the 162 NPC patients with residue at the end of IMRT in high-risk and low-risk groups.

Discussion {#S0004}
==========

In the era of two-dimensional radiotherapy, a biopsy is carried out at the interval of 2 weeks after radiotherapy for NPC. Results showed that most patients achieve complete remission 11 weeks after radiotherapy.[@CIT0015] Therefore, it is recommended that the curative effect be evaluated 3 months post-treatment, and the patients that are identified as having residual NPC should be treated again.[@CIT0016] In this study, 162 patients with NPC had a local or regional residual tumor at the end of IMRT, 62 of which achieved complete remission within 3 months, and 51 of them achieved complete remission within 6 months. Some patients had complete remission for more than 6 months. Morgan et al[@CIT0017] used human and hamster cells to study the effect of IMRT. The results showed that IMRT prolonged the effectiveness of the same dose of irradiation, and its biological side effect (cell killing) was decreased compared to conventional and rapid irradiation. Therefore, for patients with NPC treated using IMRT, the time to complete remission may be prolonged. Liu et al[@CIT0018] found that the survival of patients with residual tumor 3 months after treatment was worse than that of patients without residual tumor even after remedial treatment, which may be related to treatment interruption. Zhang et al[@CIT0004] found that image residual tumor at the end of treatment was an independent prognostic factor. Further risk stratification for these patients with poor prognosis is helpful to select high-risk patients for maintenance treatment and to avoid the effect of long-term treatment interruption. Therefore, we constructed a nomogram for the first time to predict the prognosis of patients with residual tumor at the end of IMRT, so as to start treatment as early as possible for high-risk patients, and avoid the poor effect of salvage treatment caused by an interval of 3 months.

After multivariate analysis, age emerged as an independent factor for the prognosis of OS, which is concordant with most of the current literature.[@CIT0019],[@CIT0020] Fountzilas[@CIT0021] found that NPC patients younger than 50 years old had better survival prognosis than NPC patients older than or equal to 50 years old. A study of 3880 NPC patients from SEER database also confirmed age as an independent prognostic factor, as they found that the older the patients, the higher the risk of cancer-related death.[@CIT0022] Poor overall condition, poor tolerance to radiotherapy and chemotherapy, and complications in elderly patients affect their prognosis.

He et al[@CIT0009] suggested that 95% of N-terminal and low GVTnx was related to the residual tumor of NPC patients. In NPC, the residual or recurrent cervical lymph nodes mostly occurred in areas II, III and V, often with large lymph node diameter or liquefied necrosis prone to residual tumor. Our findings indicate that N-stage and lymph node necrosis are also factors affecting prognosis, which may be due to the poor blood supply of the local tumor, the presence of hypoxic cells in the tumor, and insensitivity to radiation. Although the predictive value of TNM staging system is generally accepted, an increase of T phase and N Phase Is associated with a continued decline in the survival rate.[@CIT0023] However, T-staging was not found to affect the prognosis of patients with residual tumor after treatment ends. In these patients, there are only 4 cases of recurrence, which is far lower than the recurrence rates of most research centers. Considering that IMRT can achieve a higher dose and has superior target conformability, even in patients with late T, local control is still effective.

In this study, patients with stage I, II and the elderly were selected as the patients for radiotherapy alone. A retrospective study was performed to evaluate the efficacy of concurrent radiotherapy and chemotherapy with that of radiotherapy alone in patients receiving IMRT.[@CIT0024] The results showed that OS, LRFS and DMFS of both groups were 89.8% vs 99.0%, 94.8% vs 89.3% and 93.4% vs 97.5% in 5 years. This study suggests that the survival benefits of concurrent radiotherapy and chemotherapy in the two-dimensional era may be replaced by the survival advantages of IMRT alone, with a concurrent decrease in the incidence and degree of adverse reactions. However, there are still quite a number of clinical studies that recommend cisplatin-based chemoradiotherapy or neoadjuvant chemotherapy. Previous studies have suggested that chemotherapy can improve survival and reduce the risk of distant metastasis.[@CIT0025],[@CIT0026] In this study, multivariate regression analysis also suggested that chemotherapy could benefit in terms of long-term survival.

Our findings through multivariate Cox analysis showed that age, treatment, N-stage, and lymph node necrosis are independent prognostic factors for residual NPC after treatment ends. The obtained nomogram shows good discrimination ability (0.724; 95% CI, 0.659--0.788), and the calibration curve confirms that the predicted OS probability of nomogram is in good agreement with the actual OS probability. In addition, the score generated by nomogram enables NPC patients to be additionally classified into 2 different risk groups. Expectedly, the proposed risk groups substantially differ with regards to the risk of OS and DMFS, particularly the high-risk group. Therefore, this nomogram may represent a clinically valuable instrument for risk stratification at the end of radiotherapy to guide the next step of treatment.

However, the nomogram validated in this study has a few limitations. Firstly, this is a retrospective study of medical archives and the sample size was small, so selection bias can occur. Secondly, the nomogram is not verified externally, but we do internal verification through 1000 bootstrap copies to evade over-fitting of results. This model is easy to use and has a relatively good accuracy. With an estimate of the individual risk, clinicians can start treatment decisions as early as possible for high-risk patients with poor prognosis.
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[^1]: **Abbreviations:** WHO, World Health Organization; GTVnx, gross tumor volume of the nasopharynx; GTVnd, gross tumor volume of the positive cervical lymph node; RT, radiotherapy; IC, induction chemotherapy; CCRT, concurrent chemoradiotherapy; AC, adjuvant chemotherapy; CI, confidence interval; HR, hazard ratio.

[^2]: **Abbreviations:** GTVnx, gross tumor volume of the nasopharynx; CI, confidence interval; HR, hazard ratio.

[^3]: **Notes:** Assignment used to calculate the score. Total score= −49\*Age+66\* Chemotherapy +33.4\*N stage+49\* Lymph nodes necrosis −17.1. 3-year Survival Probability = 2.9e-08 \* Total score \^3 + −3.5863e-05 \* Total score \^2 + 0.004799804 \* Total score + 0.742595659; 5-year Survival Probability = 1.18e-07 \* Total score \^3 + −6.6583e-05 \* Total score \^2 + 0.006322075 \* Total score + 0.732145347.
